Hologic and Gen-Probe Announce Clearance from German Federal Cartel Office for Hologic's Acquisition of Gen-Probe

Hologic, Inc. (Hologic) (NASDAQ: HOLX) and Gen-Probe Incorporated (Gen-Probe) (NASDAQ: GPRO) today announced that they have received written notification from Germany's Federal Cartel Office that the proposed acquisition of Gen-Probe by Hologic is cleared to proceed.

As previously announced on June 19, 2012, the initial 30-day waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired without a request for additional information from the United States Federal Trade Commission. With the recent clearance from Germany, a required condition to close the proposed acquisition, the receipt of required anti-trust clearances has been satisfied. The acquisition remains subject to customary closing conditions, including the receipt of Gen-Probe stockholder approval.

As previously announced, on April 30, 2012, Hologic agreed to acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash. A Special Meeting of Gen-Probe stockholders has been scheduled for July 31, 2012 to vote on the pending transaction with Hologic. Gen-Probe stockholders of record as of June 29, 2012 are entitled to vote at the Special Meeting. The transaction is expected to close on or about August 1, 2012.

Additional

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.